Ardelyx, Inc.
ARDX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001437402
In the last 90 days, Ardelyx, Inc. insiders filed 0 open-market purchases and 9 sales; 250 institutions reported holding it in 13F filings for Q2 2026, worth $906.4M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Ardelyx, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 9 filings
- 8 insiders, $697.1K in total
- Insiders trading
- 8
- Net value
- −$697.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Ardelyx, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hohenleitner Susan | Chief Financial Officer | 227,520 | Aug 25, 2026 | 4 |
| Reilly Joseph James | See Remarks | 145,854 | Aug 25, 2026 | 5 |
| Bishop John E | See Remarks | 317,095 | Aug 25, 2026 | 4 |
| Brady James Parker | Chief Human Resources Officer | 245,930 | Aug 25, 2026 | 4 |
| Foster Eric Duane | Chief Commercial Officer | 409,410 | Aug 25, 2026 | 5 |
| Kelliher Mike | Chief Business Officer | 349,660 | Aug 25, 2026 | 5 |
| Williams Laura A | Chief Patient Officer | 367,456 | Aug 25, 2026 | 7 |
| Raab Michael | President & CEO | 1,619,792 | Aug 25, 2026 | 11 |
| Mott David M | Director | 3,349,655 | Jun 18, 2026 | 2 |
| Bertrand William C JR | Director | 329,507 | Jun 18, 2026 | 1 |
| Rodgers Richard J | Director | 439,998 | Jun 18, 2026 | 1 |
| Bazemore Robert B | Director | 68,006 | Jun 18, 2026 | 1 |
| Parsey Merdad | Director | 83,746 | Jun 18, 2026 | 1 |
| Cadoret-Manier Onaiza | Director | 178,156 | Jun 18, 2026 | 1 |
| Bhanji Muna | Director | 163,808 | Jun 18, 2026 | 1 |
| Grammer Elizabeth A | See Remarks | 299,895 | Nov 25, 2025 | 1 |
| Renz Justin A | Chief Financial Officer | 409,052 | Aug 25, 2025 | 0 |
| Rosenbaum David P. | Chief Development Officer | 151,373Indirect | Nov 22, 2024 | 0 |
| Blanks Robert | See Remarks | 314,421 | Nov 22, 2024 | 0 |
| Felsch Robert Ora | See Remarks | 91,560 | Aug 22, 2024 | 0 |
| Rodriguez Susan | Chief Commercial Officer | 449,092 | May 23, 2024 | 0 |
| Lundberg Jan M | Director | 146,794 | Jun 16, 2023 | 0 |
| Block Geoffrey A. | Director | – | Jun 16, 2023 | 0 |
| Sandell Scott D | 10% Owner | 2,258,850Indirect | Dec 27, 2021 | 0 |
| Baskett Forest | 10% Owner | 2,258,850Indirect | Dec 27, 2021 | 0 |
| Jacobs Jeffrey W | Chief Scientific Officer | 119,483 | Nov 24, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 24, 2021 (view filing) | Aug 20 | 4 days | Renz Justin AChief Financial Officer | SSale | −631 | $1.32 | −$832.92 | −1.6%40.0K after | |
| Aug 24, 2021 (view filing) | Aug 20 | 4 days | Raab MichaelPresident & CEO | SSale | −2.57K | $1.32 | −$3.40K | −0.8%329.7K after | |
| Aug 24, 2021 (view filing) | Aug 20 | 4 days | Jacobs Jeffrey WChief Scientific Officer | SSale | −741 | $1.32 | −$978.12 | −0.6%127.7K after | |
| Aug 24, 2021 (view filing) | Aug 20 | 4 days | Grammer Elizabeth ASee Remarks | SSale | −526 | $1.32 | −$694.32 | −0.5%102.4K after | |
| Aug 24, 2021 (view filing) | Aug 20 | 4 days | Blanks RobertSee Remarks | SSale | −631 | $1.32 | −$832.92 | −0.6%106.3K after |